Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, researchers identified a potential adverse skin reaction, called SDRIFE or Baboon syndrome, caused by the drug tofacitinib in a 19-year-old woman being treated for alopecia subtotalis, leading the authors to recommend discontinuation of the drug.

This report discusses two cases where patients continued EGFR inhibitor therapy while receiving topical treatments for SDRIFE, highlighting the importance of dermatologists in managing such cutaneous adverse events without stopping cancer treatment.